Dr Reddy's Laboratories Ltd（RDY）財務資料RDYDr Reddy's Laboratories Ltd

Dr. Reddy's Laboratories Limited (RDY) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Global Generics, accounting for 87.5% of total sales, equivalent to $719.62M. Other significant revenue streams include Pharmaceutical Services and Active Ingredients and Other. Understanding this composition is critical for investors evaluating how RDY navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Dr. Reddy's Laboratories Limited maintains a gross margin of 46.52%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 4.07%, while the net margin is 5.39%. These profitability ratios, combined with a Return on Equity (ROE) of 9.01%, provide a clear picture of how effectively RDY converts its operational activities into shareholder value.

In the context of the broader market, RDY competes directly with industry leaders such as NVO and LLY. With a market capitalization of $10.68B, it holds a significant position in the sector. When comparing efficiency, RDY's gross margin of 46.52% stands against NVO's 78.21% and LLY's 85.78%. Such benchmarking helps identify whether Dr. Reddy's Laboratories Limited is trading at a premium or discount relative to its financial performance.

Dr. Reddy's has shown fluctuating revenue, with Q2 2026 revenue at approximately $1.01 billion, but a concerning drop in net income to $24 million in Q4 2026, indicating some financial instability. The gross margin has also decreased to 44.82% in Q4 2026 from 58.68% in Q3 2025, reflecting pressure on profitability.